Journal of Molecular Science
Volume 33 Issue 3, Year of Publication 2023, Page 32-34
DoI-17.4687/1000-9035.2023.012

Journal of Molecular Science
www.jmolecularsci.com ISSN:1000-9035

The Expanding Landscape of RNA Modifications in Post-Transcriptional Gene Regulation: A Comprehensive Analysis of N6-Methyladenosine (m6A) Dynamics and Functional Implications

Isaac Matthew Roberts, Daisy May Turner, Arthur Samuel Green, Ruby Louise Hall

Article Information
Received: 21-07-2023
Revised: 08-08-2023
Accepted: 19-08-2023
Published: 23-09-2023

Keywords
Stability
Splicing
Translation efficiency

ABSTRACT

Post-transcriptional gene regulation plays a crucial role in cellular function and development. Among various RNA modifications, N6-methyladenosine (m6A) has emerged as a key player influencing RNA stability, splicing, translation efficiency, and degradation. The dynamic and reversible nature of m6A, orchestrated by methyltransferases (writers), demethylases (erasers), and reader proteins, underscores its significance in gene expression regulation. This review delves into the molecular mechanisms of m6A, its role in health and disease, and its potential as a therapeutic target. By analyzing recent advancements, we provide insights into the regulatory landscape of m6A modifications and highlight emerging trends in epitranscriptomics.

1. INTRODUCTION

RNA modifications have gained prominence as essential regulators of gene expression. Among these, m6A is the most abundant internal modification in mRNA, affecting various aspects of RNA metabolism. Studies suggest that m6A modifications influence cellular differentiation, stress responses, and oncogenic pathways. The interplay between m6A and RNA-binding proteins dictates RNA fate, making it a pivotal mechanism in post-transcriptional regulation. This article provides an in-depth exploration of m6A modifications, their regulatory mechanisms, and their implications in biological systems.

2. The Biochemical Landscape of m6A Modification



Fig.Biochemical Landscape of m6A Modification

©2023 The authors
This is an Open Access article distributed under the terms of the Creative Commons Attribution (CC BY NC), which permits unrestricted use, distribution, and reproduction in any medium, as long as the original authors and source are cited. No permission is required from the authors or the publishers.(https://creativecommons.org/licenses/by-nc/4.0/)

- **Writers (Methyltransferases):** METTL3, METTL14, and WTAP catalyze the addition of m6A to RNA. METTL3 forms the catalytic core, while METTL14 enhances its activity. WTAP acts as a scaffold, stabilizing the methyltransferase complex.
- **Erasers (Demethylases):** FTO and ALKBH5 remove m6A marks, allowing dynamic regulation. FTO has been implicated in metabolic disorders, while ALKBH5 plays a role in fertility and cancer progression.
- **Readers (RNA-binding proteins):** YTH domain-containing proteins (YTHDF1, YTHDF2, YTHDC1) recognize m6A sites, influencing RNA stability and translation. IGF2BP proteins act as stabilizers, promoting mRNA longevity.

Protein Class	Key Proteins	Functional Role
Writers	METTL3, METTL14, WTAP	Catalyze m6A methylation
Erasers	FTO, ALKBH5	Remove m6A modifications
Readers	YTHDF1, YTHDF2, YTHDC1, IGF2BP	Recognize m6A sites, regulate RNA fate

3. m6A in Cellular Processes

m6A modifications regulate several essential cellular processes, including:

- **mRNA Stability and Degradation:** m6A-marked transcripts are selectively degraded by YTHDF2, impacting gene expression.
- **Translation Efficiency:** m6A enhances translation by recruiting ribosomes, particularly under stress conditions.
- **Alternative Splicing:** YTHDC1 interacts with splicing factors to regulate exon inclusion/exclusion.
- **Stem Cell Pluripotency and Differentiation:** m6A modifications dictate cell fate transitions by controlling transcript stability.

4. m6A in Human Diseases

m6A dysregulation is implicated in various diseases, including cancer, neurological disorders, and metabolic syndromes. Alterations in m6A-modifying enzymes contribute to disease pathology:

- **Cancer:** METTL3 overexpression promotes oncogene translation, while FTO-mediated demethylation enhances tumor progression.
- **Neurodevelopmental Disorders:** m6A mutations disrupt neuronal differentiation and synaptic function.
- **Metabolic Diseases:** FTO polymorphisms are linked to obesity and type 2 diabetes.

5. Therapeutic Potential of Targeting m6A



Fig.Therapeutic Potential of Targeting m6A

The reversibility of m6A marks presents opportunities for therapeutic interventions. Small-molecule inhibitors of FTO (e.g., Rhein, FB23) show promise in cancer therapy. Targeting m6A-associated proteins may offer novel treatment strategies for various diseases.

6. CONCLUSION

Advancements in high-throughput sequencing have significantly deepened our understanding of the epitranscriptome, particularly the role of N6-methyladenosine (m6A) modifications in gene regulation, RNA stability, and translation efficiency. m6A plays a crucial role in various biological processes, including stem cell differentiation, immune response modulation, and cancer progression. Targeting m6A pathways holds immense therapeutic potential, offering novel strategies for treating diseases such as cancer, neurodegenerative disorders, and metabolic syndromes. Future research should prioritize the development of precision-targeted therapies that manipulate m6A methylation and demethylation to restore cellular homeostasis. As the field of RNA modifications continues to evolve, m6A-based therapeutics could pave the way for groundbreaking advancements in personalized medicine, providing tailored treatment approaches based on an individual's epi transcriptomic landscape.

7. REFERENCES

1. Dominissini, D., et al. (2012). "Topology of the human and mouse m6A epitranscriptome." *Nature*, 485(7397), 201-206.
2. Liu, J., et al. (2014). "A METTL3–METTL14 complex mediates mammalian nuclear RNA N6-adenosine methylation." *Nature Chemical Biology*, 10(2), 93-95.
3. Yang, Y., et al. (2018). "Dynamic m6A regulation in stress response and human disease." *Cell Research*, 28(6), 618-624.
4. Wang, X., et al. (2015). "N6-methyladenosine-dependent regulation of messenger RNA stability." *Nature*, 505(7481), 117-120.
5. Zhang, C., et al. (2017). "m6A modulates haematopoietic stem and progenitor cell specification." *Nature*, 549(7671), 273-276.
6. Zhao, B. S., et al. (2017). "Mechanistic insights into m6A modification in the mammalian epitranscriptome." *Nature Reviews Molecular Cell Biology*, 18(1), 31-42.

7. Li, Y., et al. (2020). "FTO and obesity: mechanisms and therapeutic perspectives." *Trends in Endocrinology & Metabolism*, 31(10), 758-769.
8. Su, R., et al. (2018). "Targeting FTO suppresses cancer stem cell maintenance." *Cancer Cell*, 33(5), 839-855.
9. Mauer, J., et al. (2017). "Reversible methylation of m6A in tRNA influences translation." *Nature Communications*, 8(1), 1-11.
10. Wang, Y., et al. (2014). "N6-methyladenosine modification destabilizes developmental regulators in embryonic stem cells." *Nature Cell Biology*, 16(2), 191-198.
11. Batista, P. J., et al. (2014). "m6A modulates RNA-protein interactions and gene expression." *Cell*, 159(5), 1365-1376.
12. Liu, N., et al. (2015). "Probing N6-methyladenosine RNA modification status at single-nucleotide resolution." *Nature Chemical Biology*, 11(6), 519-524.
13. Roundtree, I. A., et al. (2017). "Dynamic RNA modifications in gene expression regulation." *Cell*, 169(6), 1187-1200.